127680-76-6 Usage
General Description
2-(propylamino)isonicotinonitrile is a chemical compound with a molecular formula C10H13N3. It is a derivative of isonicotinic acid and contains a propylamine group attached to the isonicotinonitrile structure. 2-(propylamino)isonicotinonitrile is used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It has potential applications in the field of medicinal chemistry due to its versatile reactivity and ability to serve as a building block for the preparation of various biologically active molecules. The chemical properties and biological activities of 2-(propylamino)isonicotinonitrile make it a valuable tool in the development of new drugs and chemical entities.
Check Digit Verification of cas no
The CAS Registry Mumber 127680-76-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,7,6,8 and 0 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 127680-76:
(8*1)+(7*2)+(6*7)+(5*6)+(4*8)+(3*0)+(2*7)+(1*6)=146
146 % 10 = 6
So 127680-76-6 is a valid CAS Registry Number.
127680-76-6Relevant articles and documents
Discovery of an N-(2-aminopyridin-4-ylmethyl)nicotinamide derivative: A potent and orally bioavailable NCX inhibitor
Kuramochi, Takahiro,Kakefuda, Akio,Yamada, Hiroyoshi,Tsukamoto, Issei,Taguchi, Taku,Sakamoto, Shuichi
, p. 4022 - 4036 (2007/10/03)
Ca2+ overload in myocardial cells is responsible for arrhythmia. Sodium-calcium exchanger (NCX) inhibitors are more effective than sodium-hydrogen exchanger (NHE) inhibitors with regard to modulation of Ca 2+ overload, because NCX inhibitors can directly inhibit the influx of Ca2+ into cells. NCX is an attractive target for the treatment of heart failure and ischemia-reperfusion. We have designed and synthesized a series of N-(2-aminopyridin-4-ylmethyl)nicotinamide derivatives, based on compound 5. We have discovered a novel NCX inhibitor (23h) with an IC 50 value of 0.12 μM against reverse NCX. The inhibitory activities of our NCX inhibitors against cytochrome P450 were also evaluated. The effects on heart failure and the pharmacokinetic profile of compound 23h are discussed.